The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global respiratory diagnostics market size reached US$ 6.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2027, exhibiting a growth rate (CAGR) of 7.73% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sector. These insights are included in the report as a major market contributor.
Respiratory diagnostics refer to the clinical assessment of lung functioning and related processes. It includes several mechanical, imaging and molecular diagnostic tests for detecting asthma, chronic obstructive pulmonary disease (COPD), lung cancer, bronchitis, and pulmonary fibrosis. It uses procedures, such as spirometry, oximetry, transcutaneous CO2 monitoring, sniff nasal inspiratory pressure (SNIP), chest X-ray and computed tomography (CT) scan. In some instances, sleep studies are also conducted to diagnose and assess the presence of sleep apnea and nocturnal hypoventilation.
The growing prevalence of respiratory diseases is one of the key factors driving the growth of the market. The increasing number of smokers and consumption of alcohol, coupled with sedentary lifestyle habits and stressful routines, have resulted in rising incidences of COPD and other severe respiratory conditions, such as lung cancer. Furthermore, various technological innovations in respiratory diagnostic testing, including the utilization of Internet of Things (IoT) and Artificial Intelligence (AI) for the diagnosis of COPD and outpatient management, are creating a positive impact on the market growth. Also, an increase in the demand for respiratory diagnostics devices in various privately-owned hospitals and healthcare centers and efforts by both government and non-governmental organizations (NGO) to make quality healthcare facilities accessible to all are driving the market for respiratory diagnostics. Other factors contributing to the market growth include enhanced research and development (R&D), rising geriatric population, rapid urbanization and increasing industrial establishments, and growing pollution levels across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global respiratory diagnostics market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on product and service type, test type, disease and end-user.
Breakup by Product and Service Type:
Breakup by Test Type:
Breakup by Disease:
Breakup by End-User:
Breakup by Region:
The report has also analyzed the competitive landscape of the market with some of the key players being Philips Healthcare, Abbott Laboratories, Biomerieux, Becton Dickinson, Thermo Fisher Scientific Inc., Alere Inc., Seegene Inc., 3M, Bio-Rad Laboratories, SDI Diagnostics and COSMED, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product and Service Type, Test Type, Disease, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Philips Healthcare, Abbott Laboratories, Biomerieux, Becton Dickinson, Thermo Fisher Scientific Inc., Alere Inc., Seegene Inc., 3M, Bio-Rad Laboratories, SDI Diagnostics and COSMED|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at